<div id="readability-page-1"><div><h2>Regulatory milestones put Hansoh Pharmaceutical Group (SEHK:3692) pipeline in focus</h2> <p>Hansoh Pharmaceutical Group (SEHK:3692) has reported two fresh milestones from China’s National Medical Products Administration, including Breakthrough-Therapy-Designated Drug status for its oncology candidate HS-20093 and new clinical trial approvals for hypertension therapy HS-10522.</p> <p>See our latest analysis for Hansoh Pharmaceutical Group.</p> <p>Despite the regulatory momentum, Hansoh Pharmaceutical Group’s share price, which last closed at HK$36.84, shows weaker short term sentiment with a 6.4% 1 month share price decline. Its 1 year total shareholder return of 52.36% and 3 year total shareholder return of 179.15% indicate stronger performance over longer periods.</p> <p>If you are looking for other healthcare related growth stories, this could be a good moment to review 125 healthcare AI stocks</p> <p>With HS-20093 and HS-10522 gaining fresh regulatory traction, yet the stock sitting 33.20% below one intrinsic estimate and 26.29% below an analyst target, the key question is simple: is this a potential opportunity or is future growth already priced in?</p> <h2>Preferred P/E of 35x: Is it justified?</h2> <p>Hansoh Pharmaceutical Group currently trades on a P/E of 35x, which sits above both its peer group and the level suggested by one fair value estimate.</p> <p>The P/E ratio compares the share price to earnings per share, so a higher multiple usually means the market is willing to pay more today for each unit of current earnings. For a pharmaceutical company with active R&amp;D and an established product portfolio, a richer multiple can sometimes reflect expectations for continued earnings growth and the perceived resilience of cash flows.</p> <p>Here, the picture is mixed. On one hand, Hansoh is trading at a 33.2% discount to one intrinsic value estimate of HK$55.15 per share. Analysts in good agreement see scope for a 26.3% move from the current HK$36.84 level towards their HK$46.53 target. On the other hand, earnings are forecast to grow 10.8% per year, which is slower than the wider Hong Kong market forecast of 12.6% per year. The stock is also described as expensive versus an estimated fair P/E of 26.7x that the market could move towards over time.</p> <p>The comparison with peers is also stark. At 35x earnings, Hansoh is described as expensive versus the Hong Kong Pharmaceuticals industry average of 14.2x and a peer group average of 21.1x. This suggests investors are currently paying a substantial premium to sector and peer valuations for its earnings profile.</p> <p>Explore the SWS fair ratio for Hansoh Pharmaceutical Group</p> <p><strong>Result: Price-to-Earnings of 35x (OVERVALUED).</strong></p> <p>However, there are clear risks: high R&amp;D spend may not translate into successful products, and any regulatory setbacks on key candidates could quickly erode sentiment.</p> <p>Find out about the key risks to this Hansoh Pharmaceutical Group narrative.</p> <h2>Another view: DCF points in the opposite direction</h2> <p>While the 35x P/E suggests Hansoh Pharmaceutical Group trades at a premium, the SWS DCF model points the other way. With the share price at HK$36.84 versus an estimated future cash flow value of HK$55.15, the stock screens as undervalued on this framework. So which signal matters more for you?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/10ba865b-e7c9-448a-a546-f3357aebd78f/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/10ba865b-e7c9-448a-a546-f3357aebd78f/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA1"/><figcaption>3692 Discounted Cash Flow as at May 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hansoh Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 240 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>The mix of premium valuation signals and discounted cash flow estimates is hard to ignore. This is a good moment to review the numbers yourself and weigh both the concerns and the upside before sentiment shifts again, then check the full breakdown of 4 key rewards and 1 important warning sign</p> <h2>Looking for more investment ideas?</h2> <p>If you stop at one stock, you risk missing better fits for your goals, so keep widening your search and let the data help you compare opportunities.</p> <ul> <li>Zero in on potential mispricing by reviewing companies that meet the criteria in the 240 high quality undervalued stocks.</li> <li>Strengthen your income focus by scanning through the 487 dividend fortresses that may suit a yield driven approach.</li> <li>Reduce portfolio shocks by checking out the 296 resilient stocks with low risk scores that score well on resilience.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Hansoh Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

03692

510660

512290

<p>Hansoh Pharmaceutical Group (SEHK:3692) has achieved significant regulatory milestones, including Breakthrough-Therapy-Designated Drug status for HS-20093 and new trial approvals for HS-10522. Despite a recent 6.4% decline in share price, the company has shown strong long-term returns. Currently trading at a P/E of 35x, above industry averages, it raises questions about valuation. While some models suggest the stock is undervalued, risks remain due to high R&D costs and potential regulatory setbacks. Investors are advised to weigh both premium valuations and discounted cash flow estimates before making decisions.</p>

Simplywall

HANSOH PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hansoh Pharmaceutical Group SEHK 3692 Valuation After New Breakthrough Therapy And Hypertension Trial Approvals